ClinicalTrials.gg
RecruitingNCT06834594BOOSTUpdated Aug 25, 2026

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

A Phase 4 interventional study of Micronized progesterone 200 MG and Micronized Progesterone 100 MG in Turner Syndrome and Primary Ovarian Insufficiency (Poi), sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to female participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Children's Mercy Hospital Kansas City · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
12 Years to 20 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Turner Syndrome with a site in United States — 9 open to participants now, 13 under way, 3 of them phase 3. Turner Syndrome · United States.

Planned enrollment
16th of 22
40 · median 75
Started
2025
with 2 others
Phase 4
3 of 50
1 open now
Primary completion
2028-07
later than 8 of 12 live
Registered
48th of 50
by date

Among the 50 studies in Turner Syndrome with a site in United States, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 8 of the 12 other live ones, and was the 48th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

9 of the 50 studies in Turner Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 20 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Turner Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).

03

Conditions studied

  • Turner Syndrome
  • Primary Ovarian Insufficiency (Poi)

Keywords

  • Turner syndrome
  • Primary ovarian insufficiency
  • Hormone replacement therapy
04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.
  • Prescribed adult dosing* of transdermal or oral estradiol for estrogen replacement therapy.

    *Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol).

  • Have achieved menarche.

Exclusion criteria

Exclusion Criteria:

  • Disclosure of sexual activity and desire for .
  • Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.
  • Having received depot medroxyprogesterone within one year prior to study recruitment.
  • Non-English or non-Spanish speaking.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Sequential progesterone supplementation

    Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle.

    Drug: Micronized progesterone 200 MG

  • Active comparator
    Continuous progesterone supplementation:

    Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.

    Drug: Micronized Progesterone 100 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Menstrual bleeding patterns as assessed by the Pictorial Bleeding Assessment Chart (PBAC)

    PBAC is one of the most common scoring systems used in the literature to quantify menstrual blood loss (MBL) using a pictorial scoring system, with a higher score representing a larger MBL and a score \>100 qualifying as heavy menstrual bleeding

    Time frame: From enrollment to end of treatment at day 90.

Secondary outcomes

  1. Menstrual distress questionnaire (MEDI-Q)

    The Menstrual distress questionnaire (MEDI-Q) is a valid and reliable instrument for the assessment of menstrual distress and its impact on psychological well-being. This tool can be utilized in research and clinical settings to comprehensively investigate the impact of menstruation on various populations

    Time frame: From enrollment to end of treatment at day 90.

  2. Endometrial thickness.

    Endometrial thickness measured by transabdominal pelvic ultrasound.

    Time frame: On study day 90 +/- 14 days.

07

Study locations

1 of 1 sites recruiting
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Allie Ranallo · Contactalranallo@cmh.edu · +1-816-394-2574
    • Andrea Manlove · Contactalmanlove@cmh.edu · +1-816-731-7326
    • Tazim Dowlut-McElroy, M.D., M.S. · Principal investigator
    • Madeline Ross, M.D. · Sub investigator
    • Joseph Cernich, M.D. · Sub investigator
08

References and documents

Publications

  • Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, Maciel-Guerra AT, Gutmark-Little I, Fleischer K, Hong D, Klein KO, Prakash SK, Shankar RK, Sandberg DE, Sas TCJ, Skakkebaek A, Stochholm K, van der Velden JA; International Turner Syndrome Consensus Group; Backeljauw PF. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol. 2024 Jun 5;190(6):G53-G151. doi: 10.1093/ejendo/lvae050. PubMed 38748847 ↗
  • Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, Gravholt CH, Kalantaridou S, Kallen A, Kim KQ, Misrahi M, Mousa A, Nappi RE, Rocca WA, Ruan X, Teede H, Vermeulen N, Vogt E, Vincent AJ; ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024 Dec 9;2024(4):hoae065. doi: 10.1093/hropen/hoae065. eCollection 2024. PubMed 39660328 ↗
  • Dowlut-McElroy T, Kanakatti Shankar R. Hormone Replacement Therapy after Pubertal Induction in Adolescents and Young Adults with Turner Syndrome: A Survey Study. Horm Res Paediatr. 2024;97(1):62-69. doi: 10.1159/000530724. Epub 2023 Apr 24. PubMed 37094554 ↗
  • Dowlut-McElroy T, Shankar RK. The Care of Adolescents and Young Adults with Turner Syndrome: A Pediatric and Adolescent Gynecology Perspective. J Pediatr Adolesc Gynecol. 2022 Aug;35(4):429-434. doi: 10.1016/j.jpag.2022.02.002. Epub 2022 Mar 8. PubMed 35272055 ↗

Individual participant data

Plan to share: No — Protect confidentiality of individuals with this rare disease (Turner syndrome).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 19, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 31, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06834594
Responsible party
Tazim Dowlut-McElroy (Director, Division of Gynecology, Children's Mercy Hospital Kansas City) — Principal investigator
First posted
Feb 19, 2025
Start date
Jul 31, 2025
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Allie Ranallo
Contact
alranallo@cmh.edu
+1-816-394-7534
Andrea Manlove
Contact
almanlove@cmh.edu
+1-816-731-7326
Tazim Dowlut-McElroy, M.D., M.S.
principal investigator · Children's Mercy Kansas City

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progesterone

Start the discussion